In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Cesca Therapeutics (KOOL), with a price target of $1. The company’s shares closed yesterday at $0.30, close to its 52-week low of $0.21.
Ramakanth said:
“We maintain our Buy rating of Cesca Therapeutics and lower our 12-month price target to $1.00 per share, down from $1.50. We derive our price target based on a risk-adjusted NPV analysis of projected product revenues through 2030 assuming a 10% discount rate and 3% terminal growth rate.”
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -2.9% and a 34.7% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, Gritstone Oncology Inc, and IntelGenx Technologies.
Currently, the analyst consensus on Cesca Therapeutics is a Moderate Buy with an average price target of $1.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.40 and a one-year low of $0.21. Currently, Cesca Therapeutics has an average volume of 122.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cesca Therapeutics, Inc. engages in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It operates through the Clinical Development Division and Device Division business segments.
